Selank is one of a small group of synthetic peptides that emerged from Russian regulatory-peptide research and has since become a recurring subject in preclinical neuroscience. It is studied mainly in the context of anxiety and stress-related signalling, and secondarily for effects on learning, memory, and the immune system.
This article explains what Selank is, what the research has actually examined, how it is thought to work, and — just as importantly — where the evidence stops. Everything below is written for research and laboratory context. Selank is supplied for research use only by BME Health, and this article is about the published science, not about using any compound.
What Is Selank?
Selank is a synthetic heptapeptide — a chain of seven amino acids, with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a chemically stable analogue of tuftsin, a naturally occurring tetrapeptide produced when the body enzymatically cleaves immunoglobulin G (IgG). Tuftsin itself is an immunomodulatory peptide; Selank was designed to retain aspects of that activity while being stable enough to serve as a practical research tool.
That lineage matters. Because Selank is derived from an endogenous peptide rather than built as a synthetic drug from scratch, much of the early interest came from researchers asking whether a stabilised, brain-active tuftsin fragment might influence both the nervous and immune systems. It is supplied as a lyophilized powder and specified at ≥99% purity for laboratory work.
Why Selank Draws Research Interest
The recurring theme in Selank research is anxiety-related signalling. In preclinical behavioural models, researchers have observed anxiolytic-like effects — that is, changes consistent with reduced anxiety in the tests used — and a frequently noted point of interest is that these effects appeared without the sedation, muscle relaxation, or dependence liability associated with classical benzodiazepines in the same paradigms. Whether that separation holds in humans is a separate question the preclinical work cannot answer.
A second thread is the breadth of systems Selank appears to touch. Rather than acting through one clean receptor, the published literature describes effects across several pathways at once — neurotransmitter systems, neurotrophic signalling, and immune modulation. That multi-system profile is part of why it keeps appearing in mechanistic studies, and also part of why its mechanism remains incompletely characterised.
Anxiolytic Research
Most anxiolytic findings come from animal models, where Selank has been associated with anxiolytic-like behavioural changes. Beyond the preclinical work, a controlled clinical study conducted in Russia compared Selank against a benzodiazepine reference compound in patients with generalized anxiety disorder and neurasthenia; the authors reported that Selank produced an anxiolytic effect comparable to the benzodiazepine comparator, and additionally noted antiasthenic and mild activating effects that the comparator did not show (Zozulya et al., 2008).
Two limitations are worth holding onto when reading that result. First, the study was relatively small and was published in a Russian-language psychiatric journal; independent replication in Western clinical settings has not been reported. Second, a favourable comparison in one trial is a starting point for further investigation, not a settled conclusion. The anxiolytic research is best described as promising within its own literature and largely unreplicated outside it.
Cognitive and Memory Research
Alongside anxiety, Selank has been studied for effects on learning and memory in animal models. In object-recognition and related paradigms, researchers have observed cognition-supporting changes and, in some models, protection against experimentally induced memory and attention deficits. These findings are consistent with the peptide's proposed effects on neurotrophic signalling (below), but they remain preclinical, and the size and durability of any cognitive effect in humans is not established.
How It Works — Proposed Mechanisms
Selank does not have a single, agreed mechanism. The research literature instead describes several parallel routes, and the current understanding is that its effects likely arise from a combination of them.
The most discussed is modulation of the GABAergic system — the brain's primary inhibitory signalling system. Importantly, Selank does not appear to bind GABA receptors directly the way benzodiazepines do. Instead, gene-expression studies in relevant cell and animal models have shown that Selank alters the expression of genes involved in GABAergic neurotransmission, pointing to an indirect, regulatory influence rather than direct agonism (Volkova et al., 2017).
Selank has also been associated with changes in monoaminergic signalling — including the expression of serotonin- and dopamine-related transcripts — and with inhibition of the enzymes that degrade endogenous enkephalins, which would extend the activity of those endogenous opioid peptides in research systems. A further, well-documented finding is upregulation of brain-derived neurotrophic factor (BDNF): intranasal Selank was reported to regulate BDNF expression in the rat hippocampus, with transcript levels changing within hours of administration (Inozemtseva et al., 2008). BDNF supports neuronal growth and plasticity, which offers a plausible link to the cognitive findings.
Finally, because Selank is a tuftsin analogue, part of its research profile concerns immune modulation — effects on cytokine signalling inherited from the tuftsin backbone. Reviews of this class of regulatory peptides describe the compound as acting through several membrane-associated and signalling pathways simultaneously rather than a single target (Kolomin et al., 2013).
What Researchers Are Still Learning
The central caveat with Selank is the shape of its evidence base. A large share of the primary research — both mechanistic and clinical — has been published in Russian-language journals, and the human clinical work has not been independently replicated in Western trials. That does not make the findings wrong, but it does mean the wider research community has had limited opportunity to test them.
The mechanistic picture is also still being assembled. The GABAergic, monoaminergic, enkephalin, BDNF, and immune threads are each supported by studies, but exactly how they combine, and which dominate under which conditions, remains an open question. And as with most peptides at this stage, whether effects seen consistently in animal and cell models translate to humans — and at what scale — is largely unestablished. Selank remains an active preclinical research subject rather than a settled one.
How Selank Compares to Semax
Selank is often discussed alongside Semax, another synthetic peptide from the same Russian regulatory-peptide research tradition. The two are studied for overlapping but distinct purposes. Semax is a synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH 4-10) and is generally framed in the literature as the more pro-cognitive and neuroprotective of the pair. Selank, derived from tuftsin, is generally framed as the more anxiolytic and stress-modulating. Researchers interested in either will find that both share the same broad caveat: a research base concentrated in Russian-language literature with limited independent Western replication.
Research Status and Sourcing
Selank has been registered as an anxiolytic in Russia since 2009. It is not approved as a drug by the U.S. Food and Drug Administration, Health Canada, or the European Medicines Agency, and it is not authorized for sale as a health product in those jurisdictions. As with other research peptides, a "for research use only" label does not make a product approved, and it does not exempt any product from applicable regulatory requirements. Researchers are responsible for compliance with the laws that apply in their own jurisdiction.
BME Health supplies Selank as a research compound in 5 mg and 10 mg formats, specified at ≥99% purity, with a per-batch Certificate of Analysis documented through the process described on our Quality & Testing page. It is supplied for laboratory and research use only.
This article is for educational and research purposes only and is not medical advice. It does not describe or recommend any use of any compound in humans or animals.
Frequently Asked Questions
What is Selank?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stable analogue of tuftsin, a naturally occurring immunomodulatory peptide. It is studied in preclinical models for anxiolytic-like and neurotrophic effects.
How is Selank thought to work?
Research points to several proposed mechanisms rather than one: indirect modulation of the GABAergic system, changes in the expression of serotonin-, dopamine- and GABA-related genes, reduced enkephalin degradation, and upregulation of BDNF. These are findings from cell and animal models.
Is Selank approved as a drug?
It has been registered as an anxiolytic in Russia since 2009, but it is not approved by the FDA, Health Canada, or the EMA. Research-use labelling does not confer approval or exempt a product from regulatory requirements.
What are the limits of the current evidence?
Most primary research is preclinical, and much of the human clinical work is in Russian-language journals without independent Western replication. Human translation remains largely unestablished outside that literature.
References
1. Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PubMed.
2. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. DOI.
3. Volkova A, Shadrina M, Kolomin T, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89. doi:10.3389/fphar.2017.00089. Open access.
4. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience & Medicine. 2013;4(4):223-252. Full text.